Amedeo Smart

Free Medical Literature Service

 

Amedeo

Chronic Heart Failure
  Free Subscription

Articles published in
Eur Heart J
    April 2024
  1. CREA F
    The complex interaction between cancer, ischaemic heart disease, and heart failure, and a focus on arrhythmias including risk stratification in Brugada syndrome and leadless pacing.
    Eur Heart J. 2024;45:1183-1187.
    >> Share

  2. RUZIEH M
    Comparative effectiveness research using claims data: meticulous methods don't solve old problems.
    Eur Heart J. 2024;45:1284.
    >> Share

    March 2024
  3. ALCOCER-GAMBA MA, Alvarez-Sangabriel A, de la Parra-Calderon JA
    Management of heart failure in Mexico: challenges and opportunities.
    Eur Heart J. 2024 Mar 29:ehae059. doi: 10.1093.
    >> Share

  4. PEDICINO D, Volpe M
    Weekly journal scan: a hard RAFTing to improve long-term survival in heart failure with severely reduced ejection fraction.
    Eur Heart J. 2024 Mar 28:ehae167. doi: 10.1093.
    >> Share

  5. SCHUERMANS A, Vlasschaert C, Nauffal V, Cho SMJ, et al
    Clonal haematopoiesis of indeterminate potential predicts incident cardiac arrhythmias.
    Eur Heart J. 2024;45:791-805.
    >> Share

  6. CLELAND JGF, Kalra PA, Pellicori P, Graham FJ, et al
    Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.
    Eur Heart J. 2024 Mar 6:ehae086. doi: 10.1093.
    >> Share

  7. CHAIX MA, Dore A, Mondesert B, Mongeon FP, et al
    Angiotensin receptor-neprilysin inhibitor vs. placebo in congenital systemic right ventricular heart failure: the PARACYS-RV trial.
    Eur Heart J. 2024 Mar 6:ehad890. doi: 10.1093.
    >> Share

  8. SAYOUR NV, Paal AM, Ameri P, Meijers WC, et al
    Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence.
    Eur Heart J. 2024 Mar 5:ehae105. doi: 10.1093.
    >> Share

  9. MURARU D, Badano LP, Hahn RT, Lang RM, et al
    Atrial secondary tricuspid regurgitation: pathophysiology, definition, diagnosis, and treatment.
    Eur Heart J. 2024 Mar 5:ehae088. doi: 10.1093.
    >> Share


  10. Correction to: Conventional heart failure therapy in cardiac ATTR amyloidosis.
    Eur Heart J. 2024 Mar 1:ehae140. doi: 10.1093.
    >> Share

    February 2024
  11. ZURKAN D, Pitt B, Edelmann F
    Mineralocorticoid receptor antagonists for the prevention of atrial fibrillation in patients with and without heart failure: one more beneficial effect?
    Eur Heart J. 2024 Feb 6:ehae040. doi: 10.1093.
    >> Share

    January 2024
  12. BERNARDO MC, Carvalho SS, Moreira I
    Massive myocardial calcification as an aetiology of heart failure.
    Eur Heart J. 2024 Jan 23:ehae009. doi: 10.1093.
    >> Share

  13. BAUERSACHS J, de Boer RA, Zieroth S
    The year in cardiovascular medicine 2023: the top 10 papers in heart failure and cardiomyopathies.
    Eur Heart J. 2024 Jan 18:ehad878. doi: 10.1093.
    >> Share

  14. GALIUTO L, Volpe M
    A new RNA-interference based strategy is associated with mild beneficial effects in patients with heart failure due to cardiac amyloidosis.
    Eur Heart J. 2024 Jan 18:ehae015. doi: 10.1093.
    >> Share

  15. DOEHNER W, Akyea RK, Ntaios G
    The obesity paradigm on outcome in heart failure with reduced ejection fraction.
    Eur Heart J. 2024 Jan 18:ehad761. doi: 10.1093.
    >> Share

  16. BUTT JH, McMurray JJV
    The obesity paradigm on outcome in heart failure with reduced ejection fraction.
    Eur Heart J. 2024 Jan 18:ehad764. doi: 10.1093.
    >> Share

  17. AHN HJ, An HY, Ryu G, Lim J, et al
    Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study.
    Eur Heart J. 2024 Jan 17:ehad869. doi: 10.1093.
    >> Share

  18. PELLICORI P, Hunter D, Ei Khin HH, Cleland JGF, et al
    How to diagnose and treat venous congestion in heart failure.
    Eur Heart J. 2024 Jan 9:ehad883. doi: 10.1093.
    >> Share

  19. ORAII A, Healey JS, Kowalik K, Pandey AK, et al
    Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials.
    Eur Heart J. 2024 Jan 9:ehad811. doi: 10.1093.
    >> Share

  20. KAMBIC T, Lavie CJ, Eijsvogels TMH
    Seeking synergy for novel weight- and glucose-lowering pharmacotherapy and exercise training in heart failure patients with preserved ejection fraction.
    Eur Heart J. 2024 Jan 8:ehad856. doi: 10.1093.
    >> Share

    December 2023

  21. Correction to: Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry.
    Eur Heart J. 2023 Dec 21:ehad855. doi: 10.1093.
    >> Share

  22. ABU-OWN H, Webb I, Okonko DO
    Intravenous iron repletion in heart failure: bridging the gap between symptom relief and hard clinical outcomes.
    Eur Heart J. 2023;44:5092-5094.
    >> Share

  23. KRAMARENKO D, Walsh R
    Emery-Dreifuss muscular dystrophy: a closer look at cardiac complications.
    Eur Heart J. 2023;44:5074-5076.
    >> Share

  24. LI XM, Zhu XJ, Jing ZC
    Reverse cardiac remodelling after balloon atrial septostomy for pulmonary arterial hypertension and end-stage heart failure.
    Eur Heart J. 2023 Dec 16:ehad822. doi: 10.1093.
    >> Share

  25. MULLER FS, Aherrahrou Z, Grasshoff H, Heidorn MW, et al
    Autoantibodies against the chemokine receptor 3 predict cardiovascular risk.
    Eur Heart J. 2023;44:4935-4949.
    >> Share

  26. MEHRA MR, Castagna F, Butler J
    The transformative potential of left ventricular assist devices in advanced heart failure: no more a therapeutic orphan.
    Eur Heart J. 2023 Dec 11:ehad555. doi: 10.1093.
    >> Share

  27. KHAN MS, Usman MS, Van Spall HGC, Greene SJ, et al
    Endpoint adjudication in cardiovascular clinical trials.
    Eur Heart J. 2023;44:4835-4846.
    >> Share

  28. WESTWOOD M, Almeida AG, Barbato E, Delgado V, et al
    Competency-based cardiac imaging for patient-centred care. A statement of the European Society of Cardiology (ESC). With the contribution of the European Association of Cardiovascular Imaging (EACVI), and the support of the Association of Cardiovascul
    Eur Heart J. 2023;44:4771-4780.
    >> Share

    November 2023
  29. SCHMITTO JD, Shaw S, Garbade J, Gustafsson F, et al
    Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry.
    Eur Heart J. 2023 Nov 30:ehad658. doi: 10.1093.
    >> Share


  30. Correction to: 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of
    Eur Heart J. 2023 Nov 23:ehad613. doi: 10.1093.
    >> Share

  31. CREA F
    Fighting the pandemic of heart failure: better utilization of current treatments, new drugs, and new therapeutic targets.
    Eur Heart J. 2023;44:4607-4611.
    >> Share

  32. TOMII D, Praz F, Windecker S
    Guideline directed medical therapy in patients with heart failure undergoing transcatheter edge-to-edge mitral valve repair: unfulfilled premise.
    Eur Heart J. 2023 Nov 15:ehad678. doi: 10.1093.
    >> Share

  33. HENRY CM, Oseran AS, Zheng Z, Dong H, et al
    Cardiovascular Hospitalizations and Mortality Among Adults Aged 25 to 64 years in the United States.
    Eur Heart J. 2023 Nov 11:ehad772. doi: 10.1093.
    >> Share

  34. JESSEN N, Mocumbi AO, Sliwa K
    Heart failure in Africa: challenges of dealing with a heterogeneous syndrome in a heterogeneous continent.
    Eur Heart J. 2023 Nov 9:ehad742. doi: 10.1093.
    >> Share

  35. WERT L, Falk V, Potapov EV
    Severe aortic regurgitation after short-term treatment with microaxial left ventricular assist device in the transaxillary approach.
    Eur Heart J. 2023 Nov 9:ehad750. doi: 10.1093.
    >> Share

  36. KIYUNA LA, Candido DS, Bechara LRG, Jesus ICG, et al
    4-Hydroxynonenal impairs miRNA maturation in heart failure via Dicer post-translational modification.
    Eur Heart J. 2023 Nov 7:ehad662. doi: 10.1093.
    >> Share

  37. SLUIJTER JPG, Xiao J
    Post-translational modifications upon mitochondrial dysfunction in heart failure.
    Eur Heart J. 2023 Nov 6:ehad710. doi: 10.1093.
    >> Share

  38. INCIARDI RM, Solomon SD
    Beyond the rhythm: atrial fibrillation, diastolic dysfunction, and heart failure.
    Eur Heart J. 2023 Nov 3:ehad747. doi: 10.1093.
    >> Share

    October 2023
  39. RESTIVO A, Paglianiti DA, D'Amario D
    Left atrial pressure-assisted acute heart failure management in the cardiac intensive care unit: a proof-of-concept.
    Eur Heart J. 2023 Oct 26:ehad730. doi: 10.1093.
    >> Share

  40. LIUZZO G, Patrono C
    Moving a STEP forward in the treatment of patients with obesity and heart failure with preserved ejection fraction.
    Eur Heart J. 2023 Oct 25:ehad674. doi: 10.1093.
    >> Share

  41. CREA F
    Innovative trials in heart failure, dyslipidaemias, and sinus node dysfunction.
    Eur Heart J. 2023;44:4203-4207.
    >> Share

  42. PANDEY A, Kolkailah AA, Cosentino F, Cannon CP, et al
    Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
    Eur Heart J. 2023 Oct 21:ehad639. doi: 10.1093.
    >> Share

  43. DENIAU B, Costanzo MR, Sliwa K, Asakage A, et al
    Acute heart failure: current pharmacological treatment and perspectives.
    Eur Heart J. 2023 Oct 18:ehad617. doi: 10.1093.
    >> Share

  44. PEDICINO D, Volpe M
    Atrial fibrillation ablation improves outcomes in patients with end-stage heart failure: is it all gold the glitter in the CASTLE?
    Eur Heart J. 2023 Oct 17:ehad675. doi: 10.1093.
    >> Share

  45. CAI A, Qiu W, Xia S, Zhou Y, et al
    Sex-specific characteristics and outcomes in hospitalized heart failure with preserved ejection fraction: the China Cardiovascular Association Database-Heart Failure Center Registry.
    Eur Heart J. 2023 Oct 4:ehad619. doi: 10.1093.
    >> Share

  46. CREA F
    Focus on heart failure and cardiomyopathies: new ESC Guidelines and key meta-analyses.
    Eur Heart J. 2023;44:3487-3491.
    >> Share

    September 2023
  47. BORLAUG BA, Schaff HV, Asirvatham SJ, Koepp KE, et al
    Surgical pericardiotomy to treat heart failure with preserved ejection fraction: a first clinical study.
    Eur Heart J. 2023 Sep 22:ehad620. doi: 10.1093.
    >> Share

  48. MOHANTY S, La Fazia VM, Natale A
    The Antwerp score: is this the 'new hope on the horizon'?
    Eur Heart J. 2023;44:3336-3338.
    >> Share

  49. PANDEY AK, Bhatt DL, Pandey A, Marx N, et al
    Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction.
    Eur Heart J. 2023 Sep 7:ehad389. doi: 10.1093.
    >> Share

  50. CREA F
    Hot topics in congenital heart disease: tetralogy of Fallot, Ross operation, immunodeficiency, cardiac arrest, and end-stage heart failure.
    Eur Heart J. 2023;44:3201-3204.
    >> Share

  51. LADOUCEUR M
    Congenitally corrected transposition of the great arteries: have we shifted the disease 'trajectory?
    Eur Heart J. 2023;44:3292-3294.
    >> Share

  52. ANGERMANN CE, Ertl G
    Remote heart failure management guided by pulmonary artery pressure home monitoring: rewriting the future?
    Eur Heart J. 2023 Sep 6:ehad525. doi: 10.1093.
    >> Share

  53. BROWNELL NK, Fonarow GC
    Hospitalization for heart failure requires a PROMPT response.
    Eur Heart J. 2023 Sep 6:ehad444. doi: 10.1093.
    >> Share

    August 2023
  54. GHAZI L, Yamamoto Y, Fuery M, O'Connor K, et al
    Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial.
    Eur Heart J. 2023 Aug 31:ehad512. doi: 10.1093.
    >> Share

  55. LEONG DP, Joseph P, McMurray JJV, Rouleau J, et al
    Frailty and outcomes in heart failure patients from high-, middle- and low-Income countries.
    Eur Heart J. 2023 Aug 28:ehad595. doi: 10.1093.
    >> Share

  56. CANNIE DE, Syrris P, Protonotarios A, Bakalakos A, et al
    Emery-Dreifuss Muscular Dystrophy 1 is associated with high risk of malignant ventricular arrhythmias and end-stage heart failure.
    Eur Heart J. 2023 Aug 28:ehad561. doi: 10.1093.
    >> Share

  57. MCALISTER FA
    Frailty: A new Vital Sign in Heart Failure Comes of age.
    Eur Heart J. 2023 Aug 28:ehad559. doi: 10.1093.
    >> Share

  58. NASER JA, Lee E, Scott CG, Kennedy AM, et al
    Prevalence and Incidence of Diastolic Dysfunction in Atrial Fibrillation: Clinical Implications.
    Eur Heart J. 2023 Aug 28:ehad592. doi: 10.1093.
    >> Share

  59. VARSHNEY AS, Shah M, Vemulapalli S, Kosinski A, et al
    Heart Failure Medical Therapy Prior to Mitral Transcatheter Edge-to-Edge Repair: The STS/ACC Transcatheter Valve Therapy Registry.
    Eur Heart J. 2023 Aug 26:ehad584. doi: 10.1093.
    >> Share

  60. MERKELY B, Hatala R, Wranicz JK, Duray G, et al
    Upgrade of right ventricular pacing to cardiac resynchronisation therapy in heart failure: a randomised trial.
    Eur Heart J. 2023 Aug 26:ehad591. doi: 10.1093.
    >> Share

  61. LINDE C
    The BUDAPEST trial: a good grade for upgrades in heart failure with reduced ejection fraction.
    Eur Heart J. 2023 Aug 26:ehad588. doi: 10.1093.
    >> Share

  62. PONIKOWSKI P, Mentz RJ, Hernandez AF, Butler J, et al
    Efficacy of Ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.
    Eur Heart J. 2023 Aug 26:ehad586. doi: 10.1093.
    >> Share

  63. BUENO H, Packer M
    Acetazolamide for Acute Heart Failure: Is ADVOR a Riddle Wrapped in a Mystery Inside an Enigma?
    Eur Heart J. 2023 Aug 25:ehad560. doi: 10.1093.
    >> Share

  64. MEEKERS E, Dauw J, Martens P, Dhont S, et al
    Renal Function and Decongestion With Acetazolamide in Acute Decompensated Heart Failure: The ADVOR Trial.
    Eur Heart J. 2023 Aug 25:ehad557. doi: 10.1093.
    >> Share

  65. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
    2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
    Eur Heart J. 2023 Aug 25:ehad195. doi: 10.1093.
    >> Share

  66. WU J, Nadarajah R, Nakao YM, Nakao K, et al
    Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation.
    Eur Heart J. 2023 Aug 25:ehad571. doi: 10.1093.
    >> Share

  67. BAUERSACHS J, Soltani S
    Sodium-glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists synergism in heart failure: it takes two to tango.
    Eur Heart J. 2023 Aug 23:ehad540. doi: 10.1093.
    >> Share

  68. BANERJEE M, Maisnam I, Pal R, Mukhopadhyay S, et al
    Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
    Eur Heart J. 2023 Aug 22:ehad522. doi: 10.1093.
    >> Share

  69. VAN DISSEL AC, Opotowsky AR, Burchill LJ, Aboulhosn J, et al
    End-stage heart failure in congenitally corrected transposition of the great arteries: a multicentre study.
    Eur Heart J. 2023 Aug 18:ehad511. doi: 10.1093.
    >> Share

  70. CREA F
    Late breaking trials in heart failure.
    Eur Heart J. 2023;44:2877-2882.
    >> Share

  71. MARTENS P, Testani J, Damman K
    Prevention and treatment of diuretic resistance in acute heart failure: when to use which combination of diuretics?
    Eur Heart J. 2023;44:2978-2981.
    >> Share

  72. CHENG RK, Cuddy SAM
    Neurohormonal blockade in transthyretin amyloidosis: perhaps one size does not fit all?
    Eur Heart J. 2023;44:2908-2910.
    >> Share

  73. BAYES-GENIS A, Pascual-Figal D
    Making STRONGer the transition phase: personalized GDMT through NT-proBNP monitoring.
    Eur Heart J. 2023;44:2963-2965.
    >> Share

  74. NADARAJAH R, Nakao YM, Wu J, Gale CP, et al
    Using routinely collected health record data for the earlier detection of heart failure with preserved ejection fraction: FIND-HFpEF.
    Eur Heart J. 2023 Aug 3:ehad440. doi: 10.1093.
    >> Share

  75. LIN GM, Tsai KZ, Lavie CJ
    Waist-to-height ratio for the obesity paradox in heart failure: is it a matter of fitness?
    Eur Heart J. 2023 Aug 2:ehad503. doi: 10.1093.
    >> Share

  76. ROHDE LE, McMurray JJV
    REVIV(E)ing the ischaemic paradigm in heart failure: STICHes are needed.
    Eur Heart J. 2023 Aug 1:ehad488. doi: 10.1093.
    >> Share

    July 2023
  77. PEDICINO D, Volpe M
    New evidence supporting haemodynamics-guided remote management of congestion in heart failure.
    Eur Heart J. 2023 Jul 21:ehad435. doi: 10.1093.
    >> Share

  78. VERGALLO R, Patrono C
    Heart failure and socioeconomic status: global differences and inequalities.
    Eur Heart J. 2023 Jul 15:ehad410. doi: 10.1093.
    >> Share

  79. GREENE SJ, Fonarow GC
    Targeting sacubitril/valsartan for heart failure with mildly reduced or preserved ejection fraction.
    Eur Heart J. 2023 Jul 5:ehad427. doi: 10.1093.
    >> Share


  80. Corrigendum to: Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.
    Eur Heart J. 2023 Jul 3:ehad406. doi: 10.1093.
    >> Share

    June 2023
  81. BERGONTI M, Ascione C, Marcon L, Pambrun T, et al
    Left ventricular functional recovery after atrial fibrillation catheter ablation in heart failure: a prediction model.
    Eur Heart J. 2023 Jun 30:ehad428. doi: 10.1093.
    >> Share

  82. KOEHLER F, Hindricks G
    Is telemonitoring for heart failure ready after a journey longer than two decades?
    Eur Heart J. 2023 Jun 27:ehad395. doi: 10.1093.
    >> Share

  83. WITSCH J, Kasner SE
    Redefining the role of heart failure in stroke.
    Eur Heart J. 2023 Jun 26:ehad360. doi: 10.1093.
    >> Share

  84. YANG M, Kondo T, Butt JH, Abraham WT, et al
    Stroke in patients with heart failure and reduced or preserved ejection fraction.
    Eur Heart J. 2023 Jun 26:ehad338. doi: 10.1093.
    >> Share

  85. CREA F
    Challenges and opportunities in the management of acute heart failure and cardiac amyloidosis.
    Eur Heart J. 2023;44:2135-2139.
    >> Share

  86. ARNOTT C, Neal B
    Good for your heart and safe for your toes: a patient-level meta-analysis of DAPA-HF and DELIVER.
    Eur Heart J. 2023;44:2184-2186.
    >> Share

  87. TOLOMEO P, Butt JH, Kondo T, Campo G, et al
    Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial.
    Eur Heart J. 2023;44:2202-2212.
    >> Share

  88. PEDICINO D, Vergallo R
    Long-lasting effects of transcatheter repair of secondary mitral regurgitation: the latest lesson from COAPT trial.
    Eur Heart J. 2023 Jun 14:ehad349. doi: 10.1093.
    >> Share

  89. JANKOWSKA EA, Ponikowski P
    Acyl-ghrelin therapy for heart failure: already a novel inotrope or even more?
    Eur Heart J. 2023;44:2026-2028.
    >> Share

  90. CREA F
    Addressing the pandemic of heart failure: old and new therapeutic opportunities.
    Eur Heart J. 2023;44:1961-1964.
    >> Share

  91. MARTENS P, Verbrugge FH, Dauw J, Nijst P, et al
    Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial.
    Eur Heart J. 2023;44:1995-2005.
    >> Share

  92. MAHMOOD SS, Riedell PA, Feldman S, George G, et al
    Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.
    Eur Heart J. 2023;44:2029-2042.
    >> Share

  93. MARTENS P, Yu S, Larive B, Borlaug BA, et al
    Iron deficiency in pulmonary vascular disease: pathophysiological and clinical implications.
    Eur Heart J. 2023;44:1979-1991.
    >> Share

  94. CAMPBELL RT, Docherty KF
    Serum bicarbonate and congestion: a potential biomarker for identifying and guiding management in diuretic resistance?
    Eur Heart J. 2023;44:2006-2008.
    >> Share

  95. MARX N, Muller-Wieland D
    SGLT2 inhibitors in heart failure and type 2 diabetes: from efficacy in trials towards effectiveness in the real world.
    Eur Heart J. 2023 Jun 8:ehad282. doi: 10.1093.
    >> Share

  96. FU EL, Patorno E, Everett BM, Vaduganathan M, et al
    Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
    Eur Heart J. 2023 Jun 1:ehad273. doi: 10.1093.
    >> Share

    May 2023

  97. Correction to: The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies.
    Eur Heart J. 2023 May 24:ehad307. doi: 10.1093.
    >> Share

  98. BUTT JH, Kondo T, Yang M, Jhund PS, et al
    Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.
    Eur Heart J. 2023 May 23:ehad276. doi: 10.1093.
    >> Share

  99. CHATUR S, Vaduganathan M, Claggett B, Vardeny O, et al
    Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
    Eur Heart J. 2023 May 23:ehad283. doi: 10.1093.
    >> Share

  100. BORLAUG BA, Testani JM
    SGLT2 inhibitors and Diuretics in Heart Failure: Clicking Reset on the Renal Volume Setpoint?
    Eur Heart J. 2023 May 23:ehad345. doi: 10.1093.
    >> Share

  101. ADAMO M, Pagnesi M, Mebazaa A, Davison B, et al
    NT-proBNP and high-intensity care for acute heart failure: the STRONG-HF trial.
    Eur Heart J. 2023 May 22:ehad335. doi: 10.1093.
    >> Share

  102. IOANNOU A, Massa P, Patel RK, Razvi Y, et al
    Conventional heart failure therapy in cardiac ATTR amyloidosis.
    Eur Heart J. 2023 May 22:ehad347. doi: 10.1093.
    >> Share

  103. SCHOLTE NTB, Gurgoze MT, Aydin D, Theuns DAMJ, et al
    Telemonitoring for heart failure: a meta-analysis.
    Eur Heart J. 2023 May 22:ehad280. doi: 10.1093.
    >> Share

  104. CLEPHAS PRD, Radhoe SP, Boersma E, Gregson J, et al
    Efficacy of Pulmonary Artery Pressure Monitoring in Patients with Chronic Heart Failure: A Meta-Analysis of Three Randomized Controlled Trials.
    Eur Heart J. 2023 May 21:ehad346. doi: 10.1093.
    >> Share

  105. VADUGANATHAN M, Mentz RJ, Claggett BL, Miao ZM, et al
    Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
    Eur Heart J. 2023 May 21:ehad344. doi: 10.1093.
    >> Share

  106. ERN YEOH S, Osmanska J, Petrie MC, Brooksbank KJM, et al
    Dapagliflozin versus metolazone in heart failure resistant to loop diuretics.
    Eur Heart J. 2023 May 21:ehad341. doi: 10.1093.
    >> Share

  107. DAMMAN K
    Risk of knowing too much: the tricky case of estimated glomerular filtration rate and treatment decisions in heart failure.
    Eur Heart J. 2023 May 20:ehad284. doi: 10.1093.
    >> Share

  108. MULLENS W, Schulze PC, Westphal J, Bogoviku J, et al
    Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice.
    Eur Heart J. 2023 May 19:ehad266. doi: 10.1093.
    >> Share


  109. Corrigendum to: Reduced lean body mass: a potential modifiable contributor to the pathophysiology of heart failure.
    Eur Heart J. 2023 May 8:ehad272. doi: 10.1093.
    >> Share

  110. CREA F
    Heart failure with preserved ejection fraction: innovative diagnostic approaches and therapeutic targets.
    Eur Heart J. 2023;44:1481-1485.
    >> Share

  111. LEHTONEN J, Uusitalo V, Poyhonen P, Mayranpaa MI, et al
    Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis.
    Eur Heart J. 2023;44:1495-1510.
    >> Share

  112. LEE SY, Chang S, Youn JC
    Successful management of aortic root thrombosis in a patient with Heartmate 3.
    Eur Heart J. 2023;44:1578.
    >> Share

    April 2023
  113. XIN Y, Li J, Li H
    Combination diuretic therapy in acute heart failure.
    Eur Heart J. 2023 Apr 21:ehad189. doi: 10.1093.
    >> Share

  114. TRULLAS JC, Casado J, Morales-Rull JL
    Combination diuretic therapy in acute heart failure.
    Eur Heart J. 2023 Apr 21:ehad217. doi: 10.1093.
    >> Share


  115. Erratum to: Iron deficiency in heart failure across the spectrum of left ventricular ejection fraction: dotting the i's.
    Eur Heart J. 2023 Apr 20:ehad232. doi: 10.1093.
    >> Share

  116. JALLOH MB, Granger CB, Fonarow GC, Van Spall HGC, et al
    Multi-level implementation strategies to improve uptake of evidence-based therapies in heart failure.
    Eur Heart J. 2023 Apr 15:ehad150. doi: 10.1093.
    >> Share

  117. SHERROD CF, Farr SL, Sauer AJ
    Overcoming treatment inertia for patients with heart failure: how do we build systems that move us from rest to motion?
    Eur Heart J. 2023 Apr 12:ehad169. doi: 10.1093.
    >> Share

  118. VAN VELDHUISEN DJ, Bauersachs J
    Digitalis in heart failure: declining use and ongoing outcome trials.
    Eur Heart J. 2023 Apr 8:ehad185. doi: 10.1093.
    >> Share

  119. CREA F
    The link among heart failure, chronic kidney disease, and cancer: new light shed on the complex patient.
    Eur Heart J. 2023;44:1099-1102.
    >> Share

    March 2023
  120. LAM CSP, Ho JE
    Do we need dedicated heart failure with preserved ejection fraction clinics?
    Eur Heart J. 2023 Mar 29:ehad172. doi: 10.1093.
    >> Share

  121. SATO R, von Haehling S
    Revisiting the obesity paradox in heart failure: what is the best anthropometric index to gauge obesity?
    Eur Heart J. 2023 Mar 22:ehad079. doi: 10.1093.
    >> Share

  122. BUTT JH, Petrie MC, Jhund PS, Sattar N, et al
    Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox.
    Eur Heart J. 2023 Mar 22:ehad083. doi: 10.1093.
    >> Share

  123. PACKER M, Siddiqi TJ, Butler J
    Drugs that slow the progression of diabetic kidney disease: are renoprotective effects attenuated in heart failure?
    Eur Heart J. 2023 Mar 21:ehad158. doi: 10.1093.
    >> Share

  124. LIUZZO G, Volpe M
    TRANSFORM-HF closes the loop on diuretic therapy in heart failure.
    Eur Heart J. 2023 Mar 21:ehad124. doi: 10.1093.
    >> Share

  125. DIAZ-CANESTRO C, Ng HF, Yiu KH, Montero D, et al
    Reduced lean body mass: a potential modifiable contributor to the pathophysiology of heart failure.
    Eur Heart J. 2023 Mar 16:ehad130. doi: 10.1093.
    >> Share

  126. VERWERFT J, Soens L, Wynants J, Meysman M, et al
    Heart failure with preserved ejection fraction: relevance of a dedicated dyspnoea clinic.
    Eur Heart J. 2023 Mar 16:ehad141. doi: 10.1093.
    >> Share

  127. PEDICINO D, Volpe M
    Improving care for heart failure patients by COACHing clinicians to use decision-support tools.
    Eur Heart J. 2023 Mar 16:ehad097. doi: 10.1093.
    >> Share

  128. RAO VN, Giczewska A, Chiswell K, Felker GM, et al
    Long-term outcomes of phenoclusters in severe tricuspid regurgitation.
    Eur Heart J. 2023 Mar 16:ehad133. doi: 10.1093.
    >> Share

  129. LUND LH, Hage C, Pironti G, Thorvaldsen T, et al
    Acyl ghrelin improves cardiac function in heart failure and increases fractional shortening in cardiomyocytes without calcium mobilization.
    Eur Heart J. 2023 Mar 14:ehad100. doi: 10.1093.
    >> Share

  130. TAYLOR RS, Dalal HM, Zwisler AD
    Cardiac rehabilitation for heart failure: 'Cinderella' or evidence-based pillar of care?
    Eur Heart J. 2023 Mar 11:ehad118. doi: 10.1093.
    >> Share

  131. VERELST FR, Van Craenenbroeck EM, Gevaert AB
    Iron deficiency in heart failure across the spectrum of left ventricular ejection fraction: dotting the i's.
    Eur Heart J. 2023 Mar 9:ehad131. doi: 10.1093.
    >> Share

  132. SHEMESH E, Chevli PA, Islam T, German CA, et al
    Circulating ketone bodies and cardiovascular outcomes: the MESA study.
    Eur Heart J. 2023 Mar 6:ehad087. doi: 10.1093.
    >> Share

  133. KAPELIOS CJ, Benson L, Crespo-Leiro MG, Anker SD, et al
    Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry.
    Eur Heart J. 2023 Mar 4:ehad109. doi: 10.1093.
    >> Share

    February 2023
  134. CREA F
    Heart failure: from pathophysiology to deep learning-based outcome prediction.
    Eur Heart J. 2023;44:629-632.
    >> Share

  135. VOLPE M, Gallo G, Rubattu S
    Endocrine functions of the heart: from bench to bedside.
    Eur Heart J. 2023;44:643-655.
    >> Share

  136. WOUTERS PC, van de Leur RR, Vessies MB, van Stipdonk AMW, et al
    Electrocardiogram-based deep learning improves outcome prediction following cardiac resynchronization therapy.
    Eur Heart J. 2023;44:680-692.
    >> Share

  137. GAUTAM N, Mounsey JP, Yeh ETH, Al'Aref SJ, et al
    Promises and challenges of machine learning for device therapy in heart failure.
    Eur Heart J. 2023 Feb 18:ehad036. doi: 10.1093.
    >> Share

  138. VERGALLO R, Pedicino D
    Intravenous ferric derisomaltose for patients with heart failure: does iron heart translate into IRONMAN?
    Eur Heart J. 2023 Feb 14:ehad076. doi: 10.1093.
    >> Share


  139. Corrigendum to: Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).
    Eur Heart J. 2023 Feb 14:ehad059. doi: 10.1093.
    >> Share


  140. Corrigendum to: Heart Failure Association/European Society of Cardiology Atlas second edition: new insights into understanding the burden of heart failure.
    Eur Heart J. 2023 Feb 3:ehad060. doi: 10.1093.
    >> Share

  141. CREA F
    Epidemiology and treatment of acute and chronic heart failure.
    Eur Heart J. 2023;44:329-332.
    >> Share

  142. GERSH BJ, De Mets D
    Revascularization in ischaemic cardiomyopathy: how to interpret current evidence.
    Eur Heart J. 2023;44:365-367.
    >> Share

    January 2023
  143. ZHANG T, Yang X, Song J, Shi Y, et al
    Emergent transcatheter aortic valve implantation combined with enterectomy for acute decompensated heart failure caused by severe aortic stenosis and strangulated femoral hernia.
    Eur Heart J. 2023 Jan 26:ehad007. doi: 10.1093.
    >> Share


  144. Corrigendum to: Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction.
    Eur Heart J. 2023 Jan 24:ehad045. doi: 10.1093.
    >> Share

  145. BRUHN J, Malmborg M, Garred CH, Ravn P, et al
    Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study.
    Eur Heart J. 2023 Jan 24:ehac797. doi: 10.1093.
    >> Share

  146. AMERI P, Bertero E, Meijers WC
    Cancer is a comorbidity of heart failure.
    Eur Heart J. 2023 Jan 24:ehac710. doi: 10.1093.
    >> Share

  147. MARK PB, Carrero JJ, Matsushita K, Sang Y, et al
    Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study.
    Eur Heart J. 2023 Jan 24:ehac825. doi: 10.1093.
    >> Share

  148. KATO ET, Morrow DA, Guo J, Berg DD, et al
    Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis.
    Eur Heart J. 2023;44:293-300.
    >> Share

  149. WALDMANN V, Barra S, Marijon E
    Ventricular arrhythmias and sudden cardiac death in heart failure with mildly reduced or preserved ejection fraction: knowledge gaps.
    Eur Heart J. 2023 Jan 20:ehad001. doi: 10.1093.
    >> Share

  150. PEDICINO D, Volpe M
    Influenza vaccine for heart failure patients in low- and middle-income countries: another piece in the puzzle.
    Eur Heart J. 2023 Jan 14:ehac809. doi: 10.1093.
    >> Share

  151. CURTAIN JP, Adamson C, Kondo T, Butt J, et al
    Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction.
    Eur Heart J. 2023 Jan 12:ehac801. doi: 10.1093.
    >> Share

  152. DE BOER RA, Bauersachs J
    The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies.
    Eur Heart J. 2023 Jan 2:ehac781. doi: 10.1093.
    >> Share

  153. CREA F
    Acute and chronic heart failure: exciting therapeutic perspectives.
    Eur Heart J. 2023;44:1-4.
    >> Share

  154. SAVARESE G, von Haehling S, Butler J, Cleland JGF, et al
    Iron deficiency and cardiovascular disease.
    Eur Heart J. 2023;44:14-27.
    >> Share

    December 2022
  155. ZAKERI R, Wilson DG, Mohammed SF
    Time to revisit combination loop and thiazide diuretic therapy for patients with acute heart failure.
    Eur Heart J. 2022 Dec 30:ehac784. doi: 10.1093.
    >> Share

  156. OLIVOTTO I, Udelson JE, Pieroni M, Rapezzi C, et al
    Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments.
    Eur Heart J. 2022 Dec 30:ehac764. doi: 10.1093.
    >> Share

  157. CREA F
    Focus on trials: dementia, lipids, thrombosis, and heart failure.
    Eur Heart J. 2022;43:4965-4969.
    >> Share

  158. CRESPO-LEIRO MG, McDonagh TA, Barge-Caballero E
    Omecamtiv mecarbil for patients with severe systolic dysfunction and hypotension.
    Eur Heart J. 2022;43:5017-5019.
    >> Share

  159. SCHAUFELBERGER M, Basic C
    Increasing incidence of heart failure among young adults: how can we stop it?
    Eur Heart J. 2022 Dec 20:ehac730. doi: 10.1093.
    >> Share

  160. DOCHERTY KF, Jhund PS
    A welcome 'failure' of gliflozins: blood pressure reduction in heart failure.
    Eur Heart J. 2022 Dec 14:ehac712. doi: 10.1093.
    >> Share


  161. Corrigendum to: HFp2EF: heart failure with pulmonary dysfunction and preserved ejection fraction?
    Eur Heart J. 2022 Dec 12:ehac766. doi: 10.1093.
    >> Share

  162. BOHM M, Anker S, Mahfoud F, Lauder L, et al
    Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
    Eur Heart J. 2022 Dec 7:ehac693. doi: 10.1093.
    >> Share

  163. EL-CHOULI M, Meddis A, Christensen DM, Gerds TA, et al
    Lifetime risk of comorbidity in patients with simple congenital heart disease: a Danish nationwide study.
    Eur Heart J. 2022 Dec 7:ehac727. doi: 10.1093.
    >> Share

  164. LECOEUR E, Domenge O, Fayol A, Jannot AS, et al
    Epidemiology of heart failure in young adults: a French nationwide cohort study.
    Eur Heart J. 2022 Dec 1:ehac651. doi: 10.1093.
    >> Share

  165. NAGALINGAM RS, Chattopadhyaya S, Al-Hattab DS, Cheung DYC, et al
    Scleraxis and fibrosis in the pressure-overloaded heart.
    Eur Heart J. 2022;43:4739-4750.
    >> Share

    November 2022
  166. SCOTTI A, Coisne A, Taramasso M, Granada JF, et al
    Sex-Related Characteristics and Short-Term Outcomes of Patients Undergoing Transcatheter Tricuspid Valve Intervention for Tricuspid Regurgitation.
    Eur Heart J. 2022 Nov 29:ehac735. doi: 10.1093.
    >> Share

  167. HAXHA S, Halili A, Malmborg M, Pedersen-Bjergaard U, et al
    Type 2 diabetes mellitus and higher rate of complete atrioventricular block: a Danish Nationwide Registry.
    Eur Heart J. 2022 Nov 26:ehac662. doi: 10.1093.
    >> Share

  168. MEBAZAA A, Solal AC, Colombo PC
    Assessing and treating congestion in acute decompensated heart failure: are we seeing the light at the end of the tunnel?
    Eur Heart J. 2022 Nov 25:ehac680. doi: 10.1093.
    >> Share

  169. TRULLAS JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, et al
    Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.
    Eur Heart J. 2022 Nov 24:ehac689. doi: 10.1093.
    >> Share

  170. WANG B, Lee RJ, Tao L
    First-in-human transcatheter endocardial alginate-hydrogel implantation for the treatment of heart failure.
    Eur Heart J. 2022 Nov 24:ehac671. doi: 10.1093.
    >> Share

  171. VOLPE M, Patrono C
    Benefits of SGLT2i in heart failure across a broad range of ejection fractions: new opportunities and future challenges.
    Eur Heart J. 2022 Nov 12. pii: 6825243. doi: 10.1093.
    >> Share

  172. PUGLIESE NR, Masi S, Taddei S
    Rethinking albuminuria as a marker to drive treatment in congestive heart failure.
    Eur Heart J. 2022 Nov 12. pii: 6825227. doi: 10.1093.
    >> Share

  173. PATHAK S, Lai FY, Miksza J, Petrie MC, et al
    Surgical or Percutaneous Coronary Revascularisation for Heart Failure: An In Silico Model using Routinely Collected Health Data to Emulate a Clinical Trial.
    Eur Heart J. 2022 Nov 9. pii: 6815617. doi: 10.1093.
    >> Share

  174. GUTMANN C, Zelniker TA, Mayr M
    SGLT2 inhibitors in heart failure: insights from plasma proteomics.
    Eur Heart J. 2022 Nov 7. pii: 6808669. doi: 10.1093.
    >> Share

  175. OMOTE K, Borlaug BA
    Pulmonary vascular reserve with exercise in heart failure.
    Eur Heart J. 2022;43:4516-4517.
    >> Share

  176. CREA F
    Heart failure in cardio-oncology and adult congenital heart disease: new challenges and therapeutic targets.
    Eur Heart J. 2022;43:4443-4446.
    >> Share

  177. ANKER SD, Usman MS, Butler J
    'Normal weight' is really not normal in chronic disease.
    Eur Heart J. 2022;43:4418-4420.
    >> Share

    October 2022
  178. PEDICINO D, Volpe M
    From the management of altitude sickness to treatment of congestion in acute heart failure: a new season for acetazolamide?
    Eur Heart J. 2022 Oct 26. pii: 6773465. doi: 10.1093.
    >> Share

  179. JASTRZEBSKI M, Kielbasa G, Cano O, Curila K, et al
    Left bundle branch area pacing outcomes: the multicentre European MELOS study.
    Eur Heart J. 2022;43:4161-4173.
    >> Share

  180. TORBATI T, Shufelt C, Wei J, Noel Bairey Merz C, et al
    Premature menopause and cardiovascular disease: can we blame estrogen?
    Eur Heart J. 2022;43:4158-4160.
    >> Share

  181. BIEGUS J, Voors AA, Collins SP, Kosiborod MN, et al
    Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.
    Eur Heart J. 2022 Oct 18. pii: 6762535. doi: 10.1093.
    >> Share

  182. BAKRIS GL, Jaisser F
    Aldosterone excess and cardiorenal risk: more common than appreciated.
    Eur Heart J. 2022;43:3792-3793.
    >> Share

  183. SEFEROVIC PM, Rosano GMC, Vardas P, Milinkovic I, et al
    Heart Failure Association/European Society of Cardiology Atlas second edition: new insights into understanding the burden of heart failure.
    Eur Heart J. 2022 Oct 6. pii: 6750021. doi: 10.1093.
    >> Share

    September 2022
  184. VOLPE M, Pedicino D
    SGLT2 inhibitors DELIVER benefits in heart failure independently of ejection fraction and diabetes: end of the line or need for new studies?
    Eur Heart J. 2022 Sep 29. pii: 6731084. doi: 10.1093.
    >> Share

  185. BOORSMA EM, Ter Maaten JM, Damman K, van Essen BJ, et al
    Albuminuria as a marker of systemic congestion in patients with heart failure.
    Eur Heart J. 2022 Sep 23. pii: 6711732. doi: 10.1093.
    >> Share

  186. NABETA T, Kitai T, Naruse Y, Taniguchi T, et al
    Risk stratification of patients with cardiac sarcoidosis: the ILLUMINATE-CS registry.
    Eur Heart J. 2022;43:3450-3459.
    >> Share

  187. MESSERLI FH, O'Donnell M, Mente A, Yusuf S, et al
    Settling the controversy of salt substitutes and stroke: sodium reduction or potassium increase?
    Eur Heart J. 2022;43:3365-3367.
    >> Share

  188. LUFT FC
    Translating plasma sodium, stores, and hydration state from mouse to man.
    Eur Heart J. 2022;43:3349-3351.
    >> Share

  189. LUEDIKE P, Heusch G, Rassaf T
    The RUHR Heart Failure Network: improved heart failure care in a metropolitan area.
    Eur Heart J. 2022 Sep 2. pii: 6687152. doi: 10.1093.
    >> Share

    August 2022
  190. HARRINGTON J, Anker S, Butler J
    Putting the Puzzle Together: SGLT2 Inhibitors from Prevention to Treatment of Heart Failure.
    Eur Heart J. 2022 Aug 29. pii: 6677316. doi: 10.1093.
    >> Share

  191. VON LEWINSKI D, Kolesnik E, Tripolt NJ, Pferschy PN, et al
    Empagliflozin in acute Myocardial Infarction: the EMMY trial.
    Eur Heart J. 2022 Aug 29. pii: 6677315. doi: 10.1093.
    >> Share

  192. ADAMSON C, Kondo T, Jhund P, de Boer RA, et al
    Dapagliflozin for heart failure according to body mass index: the DELIVER trial.
    Eur Heart J. 2022 Aug 27. pii: 6674666. doi: 10.1093.
    >> Share

  193. ZANNAD F, Ferreira JP, Butler J, Filippatos G, et al
    Effect of Empagliflozin on Circulating Proteomics in Heart Failure: Mechanistic Insights from the EMPEROR Program.
    Eur Heart J. 2022 Aug 26. pii: 6676779. doi: 10.1093.
    >> Share

  194. KONDO T, Abdul-Rahim AH, Talebi A, Abraham WT, et al
    Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation.
    Eur Heart J. 2022 Aug 26. pii: 6676501. doi: 10.1093.
    >> Share

  195. SAGRIS D, Shantsila E, Lip GYH
    Stroke risk stratification in patients with heart failure and sinus rhythm.
    Eur Heart J. 2022 Aug 26. pii: 6676507. doi: 10.1093.
    >> Share

  196. WENZEL P
    Thromboinflammation in cardiovascular disease: lessons learned for the management of hypertension, heart failure, and aortic valve stenosis.
    Eur Heart J. 2022 Aug 18. pii: 6671020. doi: 10.1093.
    >> Share

  197. PITT B, Bhatt DL, Metra M
    Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?
    Eur Heart J. 2022 Aug 18. pii: 6670977. doi: 10.1093.
    >> Share

  198. CREA F
    The far-reaching beneficial effects of sodium-glucose co-transporter 2 inhibitors in heart failure.
    Eur Heart J. 2022;43:2907-2910.
    >> Share

  199. PANDEY AK, Bhatt DL, Cosentino F, Marx N, et al
    Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
    Eur Heart J. 2022;43:2931-2945.
    >> Share

  200. OYAMA K, Raz I, Cahn A, Kuder J, et al
    Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.
    Eur Heart J. 2022;43:2958-2967.
    >> Share

  201. MACKENZIE IS, MacDonald TM
    Serum uric acid lowering with empagliflozin in heart failure with reduced ejection fraction: a sweet added benefit?
    Eur Heart J. 2022 Aug 8. pii: 6658201. doi: 10.1093.
    >> Share

  202. PONIKOWSKI P, Biegus J
    Empagliflozin in patients hospitalized for acute heart failure.
    Eur Heart J. 2022 Aug 8. pii: 6658198. doi: 10.1093.
    >> Share

  203. SHIN J, Han K, Jung JH, Park HJ, et al
    Age at menopause and risk of heart failure and atrial fibrillation: a nationwide cohort study.
    Eur Heart J. 2022 Aug 4. pii: 6646730. doi: 10.1093.
    >> Share

  204. DACHS TM, Duca F, Rettl R, Binder-Rodriguez C, et al
    Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial.
    Eur Heart J. 2022 Aug 1. pii: 6652608. doi: 10.1093.
    >> Share

  205. BAUERSACHS J, Olsson KM
    Targeting pulmonary hypertension in patients with heart failure and preserved ejection fraction: rather static than DYNAMIC development?
    Eur Heart J. 2022 Aug 1. pii: 6652609. doi: 10.1093.
    >> Share

    July 2022
  206. BUTLER J, Anker SD, Lund LH, Coats AJS, et al
    Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.
    Eur Heart J. 2022 Jul 28. pii: 6651164. doi: 10.1093.
    >> Share

  207. PACKER M
    Potassium Binders for Patients With Heart Failure? The Real Enlightenment of the DIAMOND Trial.
    Eur Heart J. 2022 Jul 28. pii: 6651163. doi: 10.1093.
    >> Share

  208. VERGALLO R, Volpe M
    Deciphering a decision support tool (CoDE-HF) to improve the diagnosis of acute heart failure.
    Eur Heart J. 2022 Jul 22. pii: 6648207. doi: 10.1093.
    >> Share


  209. Corrigendum to: Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.
    Eur Heart J. 2022 Jul 22. pii: 6649203. doi: 10.1093.
    >> Share

  210. CREA F
    Heart failure: how to optimize guideline-directed medical therapy.
    Eur Heart J. 2022;43:2533-2537.
    >> Share

  211. HADWIGER M, Dagres N, Haug J, Wolf M, et al
    Survival of patients undergoing cardiac resynchronization therapy with or without defibrillator: the RESET-CRT project.
    Eur Heart J. 2022;43:2591-2599.
    >> Share

  212. GARG P, Gosling R, Swoboda P, Jones R, et al
    Cardiac magnetic resonance identifies raised left ventricular filling pressure: prognostic implications.
    Eur Heart J. 2022;43:2511-2522.
    >> Share

  213. OMOTE K, Sorimachi H, Obokata M, Reddy YNV, et al
    Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications.
    Eur Heart J. 2022 Jul 7. pii: 6633254. doi: 10.1093.
    >> Share

  214. DOEHNER W, Anker SD, Butler J, Zannad F, et al
    Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
    Eur Heart J. 2022 Jul 5. pii: 6631286. doi: 10.1093.
    >> Share

    June 2022
  215. GOYAL P, Kim M, Krishnan U, Mccullough SA, et al
    Post-operative atrial fibrillation and risk of heart failure hospitalization.
    Eur Heart J. 2022 Jun 28. pii: 6617280. doi: 10.1093.
    >> Share

  216. MIDDELDORP ME, Albert CM
    Post-operative AF and heart failure hospitalizations: what remains hidden in patients undergoing surgery.
    Eur Heart J. 2022 Jun 28. pii: 6617281. doi: 10.1093.
    >> Share

  217. TROMP J, Voors AA
    Heart failure medication: moving from evidence generation to implementation.
    Eur Heart J. 2022 Jun 27. pii: 6618448. doi: 10.1093.
    >> Share

  218. RAMLAKHAN KP, Malhame I, Marelli A, Rutz T, et al
    Hypertensive disorders of pregnant women with heart disease: the ESC EORP ROPAC Registry.
    Eur Heart J. 2022 Jun 21. pii: 6612238. doi: 10.1093.
    >> Share


  219. Erratum to: Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.
    Eur Heart J. 2022 Jun 18. pii: 6610027. doi: 10.1093.
    >> Share

  220. CREA F
    The complex link among heart failure, atrial fibrillation, and lung diseases, and an update on cardiac transplantation.
    Eur Heart J. 2022;43:2165-2169.
    >> Share

  221. VERMA S, Dhingra NK, Pandey AK, Cosentino F, et al
    Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure.
    Eur Heart J. 2022 Jun 10. pii: 6604931. doi: 10.1093.
    >> Share

  222. FERREIRA JP, Zannad F, Butler J, Filipattos G, et al
    Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.
    Eur Heart J. 2022 Jun 10. pii: 6605266. doi: 10.1093.
    >> Share

  223. BRAUNWALD E
    Cardiac xenotransplantation: a new path for the treatment of advanced heart failure?
    Eur Heart J. 2022 Jun 4. pii: 6601572. doi: 10.1093.
    >> Share

  224. PABEL S, Sossalla S
    Atrial fibrillation and heart failure: novel insights into the chicken and egg dilemma.
    Eur Heart J. 2022 Jun 2. pii: 6599046. doi: 10.1093.
    >> Share

    May 2022
  225. METRA M, Pagnesi M, Claggett BL, Diaz R, et al
    Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial.
    Eur Heart J. 2022 May 22. pii: 6590348. doi: 10.1093.
    >> Share

  226. CREA F
    Challenges in heart failure: from actionability of genetic variants in cardiopmyopathies to new therapeutic targets.
    Eur Heart J. 2022;43:1887-1890.
    >> Share

  227. VAN VELDHUISEN SL, Gorter TM, van Woerden G, de Boer RA, et al
    Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
    Eur Heart J. 2022;43:1955-1969.
    >> Share

  228. PARK N, Marquez J, Pham TK, Ko TH, et al
    Cereblon contributes to cardiac dysfunction by degrading Cav1.2alpha.
    Eur Heart J. 2022;43:1973-1989.
    >> Share

  229. BECHER PM, Lund LH, Coats AJS, Savarese G, et al
    An update on global epidemiology in heart failure.
    Eur Heart J. 2022 May 17. pii: 6586676. doi: 10.1093.
    >> Share

  230. BARITUSSIO A, Muthurangu V
    Cardiovascular magnetic resonance for the assessment of left ventricular filling pressure in heart failure.
    Eur Heart J. 2022 May 16. pii: 6586208. doi: 10.1093.
    >> Share

  231. ZHU Y, Ackers-Johnson M, Foo R
    T cells: a 'hidden corner' to be explored for treating heart failure.
    Eur Heart J. 2022 May 13. pii: 6585106. doi: 10.1093.
    >> Share

  232. FRANTZ S, Hundertmark MJ, Schulz-Menger J, Bengel FM, et al
    Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies.
    Eur Heart J. 2022 May 4. pii: 6578707. doi: 10.1093.
    >> Share

  233. LINDE C
    CRT-P or CRT-D in heart failure patients: the RESET-CRT project-a prelude to the randomized controlled RESET-CRT study.
    Eur Heart J. 2022 May 3. pii: 6577069. doi: 10.1093.
    >> Share

  234. COWIE MR, Cleland JGF
    The COVID-19 pandemic and heart failure: lessons from GUIDE-HF.
    Eur Heart J. 2022 May 2. pii: 6576548. doi: 10.1093.
    >> Share

  235. TRIBOUILLOY C, Bohbot Y, Kubala M, Ruschitzka F, et al
    Characteristics, management, and outcomes of patients with multiple native valvular heart disease: a substudy of the EURObservational Research Programme Valvular Heart Disease II Survey.
    Eur Heart J. 2022 May 2. pii: 6576528. doi: 10.1093.
    >> Share

    April 2022
  236. ECKHARDT CM, Balte PP, Barr RG, Bertoni AG, et al
    Lung function impairment and risk of incident heart failure: the NHLBI Pooled Cohorts Study.
    Eur Heart J. 2022 Apr 25. pii: 6573769. doi: 10.1093.
    >> Share

  237. SHEN L, Jhund PS, Docherty KF, Vaduganathan M, et al
    Accelerated and personalized therapy for heart failure with reduced ejection fraction.
    Eur Heart J. 2022 Apr 25. pii: 6573857. doi: 10.1093.
    >> Share

  238. MARON BA, Humbert M
    HFp2EF: heart failure with pulmonary dysfunction and preserved ejection fraction?
    Eur Heart J. 2022 Apr 25. pii: 6573597. doi: 10.1093.
    >> Share

  239. AKTAA S, Batra G, Cleland JGF, Coats A, et al
    Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).
    Eur Heart J. 2022 Apr 20. pii: 6571493. doi: 10.1093.
    >> Share

  240. VERBRUGGE FH, Borlaug BA
    Heart failure with normal natriuretic peptide levels: more fat, and that is the main problem.
    Eur Heart J. 2022 Apr 20. pii: 6571179. doi: 10.1093.
    >> Share

  241. VAN DER MEER P, Rienstra M, van Veldhuisen DJ
    A deleterious interaction between omecamtiv mecarbil and atrial fibrillation in patients with heart failure: an influence of digoxin?
    Eur Heart J. 2022 Apr 20. pii: 6571185. doi: 10.1093.
    >> Share

  242. OLIVELLA A, Mendez AB, Ferreira-Gonzalez I
    Mixing the fat with water: are normal natriuretic peptide heart failure with preserved ejection fraction patients just more obese?
    Eur Heart J. 2022 Apr 20. pii: 6571173. doi: 10.1093.
    >> Share

  243. CRESPO-LEIRO MG, Costanzo MR, Gustafsson F, Khush KK, et al
    Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies.
    Eur Heart J. 2022 Apr 20. pii: 6571226. doi: 10.1093.
    >> Share

  244. HONG S, Kim KS, Han K, Park CY, et al
    Acromegaly and cardiovascular outcomes: a cohort study.
    Eur Heart J. 2022;43:1491-1499.
    >> Share

  245. WACHTER R, Rommel KP
    Hospitalization for heart failure: a window of opportunity.
    Eur Heart J. 2022 Apr 13. pii: 6568144. doi: 10.1093.
    >> Share

  246. TROMP J, Ouwerkerk W, Teng TK, Cleland JGF, et al
    Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction.
    Eur Heart J. 2022 Apr 8. pii: 6564923. doi: 10.1093.
    >> Share

  247. KHAN MS, Bakris GL, Packer M, Shahid I, et al
    Kidney function assessment and endpoint ascertainment in clinical trials.
    Eur Heart J. 2022;43:1379-1400.
    >> Share

    March 2022
  248. DMITRIEVA NI, Liu D, Wu CO, Boehm M, et al
    Middle age serum sodium levels in the upper part of normal range and risk of heart failure.
    Eur Heart J. 2022 Mar 29. pii: 6553797. doi: 10.1093.
    >> Share

  249. SOLOMON SD, Claggett BL, Miao ZM, Diaz R, et al
    Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.
    Eur Heart J. 2022 Mar 23. pii: 6552734. doi: 10.1093.
    >> Share

  250. OKA S, Endo H, Takagi K, Yamagata K, et al
    Mechanical coronary artery stenosis induced by active fixation left ventricular lead: a case of acute complication after cardiac resynchronization therapy device implantation.
    Eur Heart J. 2022;43:1271.
    >> Share

  251. SHAH SJ
    BNP: Biomarker Not Perfect in heart failure with preserved ejection fraction.
    Eur Heart J. 2022 Mar 18. pii: 6550399. doi: 10.1093.
    >> Share

  252. SEQUEIRA V, Maack C
    Cereblon, a novel target in heart failure: but is calcium really everything?
    Eur Heart J. 2022 Mar 16. pii: 6549181. doi: 10.1093.
    >> Share


  253. Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries.
    Eur Heart J. 2022;43:1104-1120.
    >> Share


  254. Corrigendum to: Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology.
    Eur Heart J. 2022 Mar 11. pii: 6546740. doi: 10.1093.
    >> Share

  255. ZILE MR, Desai AS, Costanzo MR, Ducharme A, et al
    The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic.
    Eur Heart J. 2022 Mar 10. pii: 6546019. doi: 10.1093.
    >> Share

  256. PRINZEN FW, Auricchio A, Mullens W, Linde C, et al
    Electrical management of heart failure: from pathophysiology to treatment.
    Eur Heart J. 2022 Mar 10. pii: 6546052. doi: 10.1093.
    >> Share

  257. VOLPE M, Liuzzo G
    Unloading left heart with a shunt device shows no benefits in heart failure with preserved ejection fraction but supports the importance of phenotyping patients in clinical trials.
    Eur Heart J. 2022 Mar 8. pii: 6544808. doi: 10.1093.
    >> Share

    February 2022
  258. LIUZZO G, Patrono C
    In vivo generated chimeric antigen receptor T cells reduce fibrosis and restore cardiac function in experimental heart failure.
    Eur Heart J. 2022 Feb 21. pii: 6533290. doi: 10.1093.
    >> Share

  259. RUDOLPH V
    Heart and kidney: towards an integrated approach to secondary mitral regurgitation.
    Eur Heart J. 2022 Feb 18. pii: 6530471. doi: 10.1093.
    >> Share


  260. Corrigendum to: PCSK9 Inhibition in Patients with Heart Failure - Neutral or harmful intervention?
    Eur Heart J. 2022 Feb 15. pii: 6529357. doi: 10.1093.
    >> Share

  261. MUTAGAYWA RK, Chin A, Karaye K, Bonny A, et al
    Unmet needs in the management of arrhythmias among heart failure patients in Africa.
    Eur Heart J. 2022 Feb 15. pii: 6528559. doi: 10.1093.
    >> Share

  262. BRAUNWALD E
    Heart failure: a 70 year Odysseydagger.
    Eur Heart J. 2022 Feb 15. pii: 6528592. doi: 10.1093.
    >> Share


  263. Corrigendum to: Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models.
    Eur Heart J. 2022 Feb 9. pii: 6525416. doi: 10.1093.
    >> Share

  264. VERBRUGGE FH, Omote K, Reddy YNV, Sorimachi H, et al
    Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality.
    Eur Heart J. 2022 Feb 9. pii: 6525335. doi: 10.1093.
    >> Share

  265. BEOHAR N, Ailawadi G, Kotinkaduwa LN, Redfors B, et al
    Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial.
    Eur Heart J. 2022 Feb 3. pii: 6521532. doi: 10.1093.
    >> Share

  266. CREA F
    Treatment of heart failure across the spectrum of left ventricular ejection fraction and an update on cardiac amyloidosis and ischaemic cardiomyopathy.
    Eur Heart J. 2022;43:351-354.
    >> Share

    January 2022
  267. RUILOPE LM, Ruiz-Hurtado G, Miranda B, Ortiz A, et al
    Use of chronic kidney disease blind spot to prevent cardiorenal outcomes.
    Eur Heart J. 2022;43:257-260.
    >> Share

  268. NIESSNER A, Drexel H
    PCSK9 inhibition in patients with heart failure: neutral or harmful intervention?
    Eur Heart J. 2022 Jan 13. pii: 6507289. doi: 10.1093.
    >> Share

  269. BAUERSACHS J, de Boer RA, Lindenfeld J, Bozkurt B, et al
    The year in cardiovascular medicine 2021: heart failure and cardiomyopathies.
    Eur Heart J. 2022 Jan 3. pii: 6491391. doi: 10.1093.
    >> Share

    December 2021
  270. CREA F
    Sodium-glucose co-transporter inhibitors, iron therapy, and checkpoint inhibitors: new clinical and translational pieces of the heart failure puzzle.
    Eur Heart J. 2021;42:4871-4875.
    >> Share

  271. JOSEPH S, Panniyammakal J, Abdullakutty J, S S, et al
    The Cardiology Society of India-Kerala Acute Heart Failure Registry: poor adherence to guideline-directed medical therapy.
    Eur Heart J. 2021 Dec 21. pii: 6471440. doi: 10.1093.
    >> Share

  272. ZANNAD F
    Management of heart failure around the globe. Are we doing enough?
    Eur Heart J. 2021 Dec 21. pii: 6471439. doi: 10.1093.
    >> Share

  273. MARTENS P, Dupont M, Dauw J, Nijst P, et al
    The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial.
    Eur Heart J. 2021;42:4905-4914.
    >> Share

  274. WHITE HD, Schwartz GG, Szarek M, Bhatt DL, et al
    Alirocumab after acute coronary syndrome in patients with a history of heart failure.
    Eur Heart J. 2021 Dec 18. pii: 6469637. doi: 10.1093.
    >> Share

  275. ADAMO M, Gardner RS, McDonagh TA, Metra M, et al
    The 'Ten Commandments' of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
    Eur Heart J. 2021 Dec 18. pii: 6469680. doi: 10.1093.
    >> Share

  276. JANKOWSKA EA, Ponikowski P
    Dilemmas on diagnosis and treatment of iron deficiency in patients after an episode of acute heart failure.
    Eur Heart J. 2021 Dec 9. pii: 6458058. doi: 10.1093.
    >> Share

  277. SAWICKI KT, Ardehali H
    Iron therapy on quality of life in acute heart failure: alternative approaches.
    Eur Heart J. 2021 Dec 9. pii: 6458062. doi: 10.1093.
    >> Share

  278. KONDO T, McMurray JJV
    Re-emergence of heart failure with a normal ejection fraction?
    Eur Heart J. 2021 Dec 8. pii: 6455984. doi: 10.1093.
    >> Share

  279. BUTLER J, Packer M, Filippatos G, Ferreira JP, et al
    Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction.
    Eur Heart J. 2021 Dec 8. pii: 6455932. doi: 10.1093.
    >> Share

  280. COATS AJS, Heymans S, Farmakis D, Anker SD, et al
    Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology.
    Eur Heart J. 2021 Dec 7. pii: 6454842. doi: 10.1093.
    >> Share

  281. VOLPE M, Patrono C
    The EMPEROR-Preserved study: end of the search for the "Phoenix" or beginning of a new season for trials in heart failure with preserved ejection fraction.
    Eur Heart J. 2021;42:4621-4623.
    >> Share

    November 2021
  282. ROALFE AK, Lay-Flurrie SL, Ordonez-Mena JM, Goyder CR, et al
    Long term trends in natriuretic peptide testing for heart failure in UK primary care: a cohort study.
    Eur Heart J. 2021 Nov 30. pii: 6437771. doi: 10.1093.
    >> Share

  283. CRUMP C, Sundquist J, McLaughlin MA, Dolan SM, et al
    Pre-term delivery and long-term risk of heart failure in women: a national cohort and co-sibling study.
    Eur Heart J. 2021 Nov 24. pii: 6438093. doi: 10.1093.
    >> Share

  284. CREA F
    Mechanisms of heart failure with preserved ejection fraction, risk stratification of heart failure with reduced ejection fraction, and new light on resistance to diuretics in acute decompensated heart failure.
    Eur Heart J. 2021;42:4405-4409.
    >> Share

  285. PITT B, Ferreira JP, Zannad F
    Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI.
    Eur Heart J. 2021 Nov 12. pii: 6425576. doi: 10.1093.
    >> Share

  286. ISHIURA J, Nakamori S, Ishida M, Dohi K, et al
    'Targeting the cardiac myocyte and fibrosis' in heart failure.
    Eur Heart J. 2021 Nov 10. pii: 6425003. doi: 10.1093.
    >> Share

  287. LUND LH, Hage C, Savarese G
    Implementation science and potential for screening in heart failure.
    Eur Heart J. 2021 Nov 9. pii: 6424186. doi: 10.1093.
    >> Share

  288. EGIDY ASSENZA G, Dimopoulos K, Budts W, Donti A, et al
    Management of acute cardiovascular complications in pregnancy.
    Eur Heart J. 2021;42:4224-4240.
    >> Share

    October 2021
  289. BUTLER J, Anker SD, Filippatos G, Usman MS, et al
    Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations.
    Eur Heart J. 2021 Oct 30. pii: 6414464. doi: 10.1093.
    >> Share

  290. SEFEROVIC PM, Piepoli M, Polovina M, Milinkovic I, et al
    ESC/HFA Quality of Care Centres: the ultimate frontier in unifying heart failure management.
    Eur Heart J. 2021 Oct 28. pii: 6413707. doi: 10.1093.
    >> Share

  291. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
    Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the
    Eur Heart J. 2021 Oct 14. pii: 6397185. doi: 10.1093.
    >> Share

  292. BRAUNWALD E
    Heart failure with preserved ejection fraction: a stepchild no more!
    Eur Heart J. 2021;42:3900-3901.
    >> Share

  293. SATTAR N, Anker SD, Butler J, Verma S, et al
    Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights.
    Eur Heart J. 2021 Oct 7. pii: 6383062. doi: 10.1093.
    >> Share

  294. LINDE C
    Pace and ablate better than drugs in patients with heart failure and atrial fibrillation: lessons from the APAF-CRT mortality trial.
    Eur Heart J. 2021 Oct 6. pii: 6382271. doi: 10.1093.
    >> Share

    September 2021
  295. CREA F
    The ESC Guidelines on heart failure, sacubitril-valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy.
    Eur Heart J. 2021;42:3581-3585.
    >> Share

  296. ZHAO Y, Ling S, Li J, Zhong G, et al
    3' untranslated region of Ckip-1 inhibits cardiac hypertrophy independently of its cognate protein.
    Eur Heart J. 2021;42:3786-3799.
    >> Share

  297. CHEN QQ, Ma G, Liu JF, Cai YY, et al
    Neuraminidase 1 is a driver of experimental cardiac hypertrophy.
    Eur Heart J. 2021;42:3770-3782.
    >> Share

  298. WUSSLER D, Mueller C
    Biomarker-driven prognostic model for risk prediction in heart failure: ready for Prime time?
    Eur Heart J. 2021 Sep 17. pii: 6371853. doi: 10.1093.
    >> Share

  299. SINHA A, Rahman H, Webb A, Shah AM, et al
    Untangling the pathophysiologic link between coronary microvascular dysfunction and heart failure with preserved ejection fraction.
    Eur Heart J. 2021 Sep 16. pii: 6371296. doi: 10.1093.
    >> Share

  300. MARTENS P, Tang WHW, Mullens W
    Renal sodium avidity, the prevailing renal target in heart failure.
    Eur Heart J. 2021 Sep 16. pii: 6371295. doi: 10.1093.
    >> Share

  301. COX ZL, Rao VS, Ivey-Miranda JB, Moreno-Villagomez J, et al
    Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure.
    Eur Heart J. 2021 Sep 16. pii: 6371304. doi: 10.1093.
    >> Share


  302. Erratum to: CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure.
    Eur Heart J. 2021 Sep 14. pii: 6370281. doi: 10.1093.
    >> Share

  303. JANKOWSKA EA, Ponikowski P
    Intravenous iron supplementation: novel anti-remodelling therapy for patients with heart failure?
    Eur Heart J. 2021 Sep 14. pii: 6370026. doi: 10.1093.
    >> Share

  304. CREA F
    The ESC Guidelines on cardiac pacing and resynchronization, and the many facets of atrial fibrillation.
    Eur Heart J. 2021;42:3411-3414.
    >> Share

  305. GLIKSON M, Nielsen JC, Kronborg MB, Michowitz Y, et al
    2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.
    Eur Heart J. 2021;42:3427-3520.
    >> Share

  306. BAYES-GENIS A, Diez J
    Transition to heart failure in hypertension: going to the heart of the matter.
    Eur Heart J. 2021 Sep 13. pii: 6369562. doi: 10.1093.
    >> Share

  307. LEWIS EF
    A fourth pillar for all in the treatment of heart failure.
    Eur Heart J. 2021 Sep 13. pii: 6369563. doi: 10.1093.
    >> Share

  308. KAHN M, Grayson AD, Chaggar PS, Ng Kam Chuen MJ, et al
    Primary care heart failure service identifies a missed cohort of heart failure patients with reduced ejection fraction.
    Eur Heart J. 2021 Sep 11. pii: 6368904. doi: 10.1093.
    >> Share

  309. BROWN JM, Zhou W, Weber B, Divakaran S, et al
    Low coronary flow relative to myocardial mass predicts heart failure in symptomatic hypertensive patients with no obstructive coronary artery disease.
    Eur Heart J. 2021 Sep 7. pii: 6365821. doi: 10.1093.
    >> Share

    August 2021
  310. YILMAZ MB
    Does early angiography pave the way for improved outcomes in patients with acute heart failure?
    Eur Heart J. 2021 Aug 31. pii: 6360027. doi: 10.1093.
    >> Share

  311. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
    2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
    Eur Heart J. 2021 Aug 27. pii: 6358045. doi: 10.1093.
    >> Share

  312. LIGHT PE
    Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure.
    Eur Heart J. 2021 Aug 27. pii: 6358226. doi: 10.1093.
    >> Share

  313. CURTAIN JP, Docherty KF, Jhund PS, Petrie MC, et al
    Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.
    Eur Heart J. 2021 Aug 27. pii: 6358075. doi: 10.1093.
    >> Share

  314. POCOCK SJ, Ferreira JP, Gregson J, Anker SD, et al
    Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial.
    Eur Heart J. 2021 Aug 23. pii: 6356321. doi: 10.1093.
    >> Share

  315. CREA F
    The complex relationship among heart failure, cancer, and lipid lowering, and an update on cardiomyopathies.
    Eur Heart J. 2021;42:3029-3032.
    >> Share

  316. BERGER M, Solelhac G, Roche F, Heinzer R, et al
    Insomnia, a new modifiable risk factor for heart failure?
    Eur Heart J. 2021 Aug 21. pii: 6355986. doi: 10.1093.
    >> Share

  317. WITHAAR C, Lam CSP, Schiattarella GG, de Boer RA, et al
    Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models.
    Eur Heart J. 2021 Aug 20. pii: 6355308. doi: 10.1093.
    >> Share

  318. KEMPF T
    Iron supplementation in acute heart failure: energize your life.
    Eur Heart J. 2021;42:3021-3022.
    >> Share

  319. VOLPE M, Gallo G
    Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?
    Eur Heart J. 2021 Aug 15. pii: 6352588. doi: 10.1093.
    >> Share

  320. MAHMOOD A, Ray M, Dobalian A, Ward KD, et al
    Insomnia symptoms and incident heart failure: a population-based cohort study.
    Eur Heart J. 2021 Aug 15. pii: 6352589. doi: 10.1093.
    >> Share

  321. WAGNER JUG, Dimmeler S
    The endothelial niche in heart failure: from development to regeneration.
    Eur Heart J. 2021 Aug 15. pii: 6352586. doi: 10.1093.
    >> Share

  322. JACKSON AM, Jhund PS, Anand IS, Dungen HD, et al
    Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
    Eur Heart J. 2021 Aug 15. pii: 6352587. doi: 10.1093.
    >> Share

  323. DIVAKARAN S, Nohria A
    Decoding the link between heart failure and incident cancer.
    Eur Heart J. 2021 Aug 14. pii: 6352225. doi: 10.1093.
    >> Share

  324. WANG N, Sun Y, Zhang H, Wang B, et al
    Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease.
    Eur Heart J. 2021 Aug 10. pii: 6347324. doi: 10.1093.
    >> Share

  325. NICHOLLS M
    New perspectives on heart failure.
    Eur Heart J. 2021 Aug 6. pii: 6343116. doi: 10.1093.
    >> Share

    July 2021
  326. KOSYAKOVSKY LB, Austin PC, Ross HJ, Wang X, et al
    Early invasive coronary angiography and acute ischaemic heart failure outcomes.
    Eur Heart J. 2021 Jul 30. pii: 6331345. doi: 10.1093.
    >> Share

  327. TUAL-CHALOT S, Stellos K
    Drug repurposing to prevent pressure overload-induced cardiac hypertrophy and heart failure.
    Eur Heart J. 2021 Jul 13. pii: 6319852. doi: 10.1093.
    >> Share

  328. DA DALT L, Castiglioni L, Baragetti A, Audano M, et al
    PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction.
    Eur Heart J. 2021 Jul 12. pii: 6319627. doi: 10.1093.
    >> Share


  329. European Heart Journal Team Heart Failure.
    Eur Heart J. 2021 Jul 5. pii: 6314555. doi: 10.1093.
    >> Share

  330. ONO M, Garg S, Onuma Y, Serruys PW, et al
    Coronary artery bypass grafting versus percutaneous coronary intervention in ischaemic heart failure. Can reliable treatment decisions in high-risk patients be based on non-randomized data?
    Eur Heart J. 2021 Jul 1. pii: 6311994. doi: 10.1093.
    >> Share

    June 2021
  331. LAM CSP, Ferreira JP, Pfarr E, Sim D, et al
    Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
    Eur Heart J. 2021 Jun 29. pii: 6310468. doi: 10.1093.
    >> Share

  332. REN QW, Yu SY, Teng TK, Li X, et al
    Statin associated lower cancer risk and related mortality in patients with heart failure.
    Eur Heart J. 2021 Jun 22. pii: 6307232. doi: 10.1093.
    >> Share

  333. CREA F
    The Universal Definition of Heart Failure, risk prediction in cardiogenic shock, artificial intelligence in cardiac allograft rejection, and the genetics of dilated cardiomyopathy.
    Eur Heart J. 2021;42:2317-2320.
    >> Share

  334. NICHOLLS M
    Recognition for heart failure breakthrough.
    Eur Heart J. 2021 Jun 11. pii: 6296965. doi: 10.1093.
    >> Share

  335. JANKOWSKA EA, Kirwan BA, Kosiborod M, Butler J, et al
    The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
    Eur Heart J. 2021 Jun 3. pii: 6291468. doi: 10.1093.
    >> Share

  336. ZANNAD F, Cotter G, Alonso Garcia A, George S, et al
    What can heart failure trialists learn from oncology trialists?
    Eur Heart J. 2021 Jun 2. pii: 6291019. doi: 10.1093.
    >> Share

    May 2021
  337. VOLZ S, Redfors B, Angeras O, Ioanes D, et al
    Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Eur Heart J. 2021 May 23. pii: 6282431. doi: 10.1093.
    >> Share

  338. MARSTON NA, Han L, Olivotto I, Day SM, et al
    Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy.
    Eur Heart J. 2021;42:1988-1996.
    >> Share

  339. PORCHER R, Desguerre I, Amthor H, Chabrol B, et al
    Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy-analysis of registry data.
    Eur Heart J. 2021;42:1976-1984.
    >> Share

  340. HAMDANI N, Costantino S, Mugge A, Lebeche D, et al
    Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies.
    Eur Heart J. 2021;42:1940-1958.
    >> Share

  341. NICHOLLS M
    Telemedicine for chronic heart failure patients.
    Eur Heart J. 2021 May 13. pii: 6274945. doi: 10.1093.
    >> Share

  342. HAMDANI N, Costantino S, Mugge A, Lebeche D, et al
    Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies.
    Eur Heart J. 2021 May 5. pii: 6264879. doi: 10.1093.
    >> Share

    April 2021

  343. Corrigendum to: Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23.
    Eur Heart J. 2021 Apr 24. pii: 6248970. doi: 10.1093.
    >> Share

  344. CREA F
    Emerging causes and risk factors of heart failure: amyloidosis, myocarditis, immune checkpoint inhibitors, air pollution, and visceral adipose tissue.
    Eur Heart J. 2021;42:1533-1537.
    >> Share

  345. RAJAGOPALAN S, Brook RD, Al-Kindi S
    Air pollution and flooding in the lungs: modern insights into ancient problems.
    Eur Heart J. 2021;42:1592-1594.
    >> Share

  346. WITHAAR C, Meems LMG, de Boer RA
    Fighting HFpEF in women: taking aim at belly fat.
    Eur Heart J. 2021;42:1606-1608.
    >> Share

  347. FULLENKAMP DE, Puckelwartz MJ, McNally EM
    Genome-wide association for heart failure: from discovery to clinical use.
    Eur Heart J. 2021 Apr 14. pii: 6225796. doi: 10.1093.
    >> Share


  348. Erratum to: Conducting Clinical Trials in Heart Failure During (and After) the COVID-19 Pandemic: An Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Eur Heart J. 2021 Apr 7. pii: 6214477. doi: 10.1093.
    >> Share

  349. BAUERSACHS J
    The struggle towards a Universal Definition of Heart Failure-how to proceed?
    Eur Heart J. 2021 Apr 1. pii: 6206998. doi: 10.1093.
    >> Share

    March 2021
  350. CREA F
    Challenges in heart failure: quality of life, chronic kidney disease, and secondary mitral regurgitation.
    Eur Heart J. 2021;42:1185-1189.
    >> Share

  351. SPERTUS JA
    Quality of life in EMPEROR-Reduced: emphasizing what is important to patients while identifying strategies to support more patient-centred care.
    Eur Heart J. 2021;42:1213-1215.
    >> Share

  352. FUKUOKA R, Kawamura A, Kohsaka S
    Prediction of sudden arrhythmic death in patients with heart failure: towards validation in a worldwide broader range of patients.
    Eur Heart J. 2021 Mar 18. pii: 6177055. doi: 10.1093.
    >> Share

  353. COATS AJS, Anker SD, Baumbach A, Alfieri O, et al
    The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and
    Eur Heart J. 2021 Mar 18. pii: 6174642. doi: 10.1093.
    >> Share

  354. YOUNIS A, Goldenberg I
    Extending the MADIT-ICD benefit score to heterogenous heart failure populations.
    Eur Heart J. 2021 Mar 18. pii: 6177051. doi: 10.1093.
    >> Share

  355. VOLPE M, Patrono C
    The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending.
    Eur Heart J. 2021 Mar 10. pii: 6168016. doi: 10.1093.
    >> Share

  356. GARNIER S, Harakalova M, Weiss S, Mokry M, et al
    Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23.
    Eur Heart J. 2021 Mar 3. pii: 6157424. doi: 10.1093.
    >> Share

  357. VAN DIEPEN S, Armstrong PW
    Learning whether to subtract beta-blockers: it's about time.
    Eur Heart J. 2021;42:915-918.
    >> Share

    February 2021
  358. VOLPE M, Patrono C
    Iron heart.
    Eur Heart J. 2021;42:809-810.
    >> Share

  359. DIDERIKSEN JR, Christiansen MK, Johansen JB, Nielsen JC, et al
    Long-term outcomes in young patients with atrioventricular block of unknown aetiology.
    Eur Heart J. 2021 Feb 18. pii: 6143533. doi: 10.1093.
    >> Share

  360. VILLRINGER A, Laufs U
    Heart failure, cognition, and brain damage.
    Eur Heart J. 2021 Feb 16. pii: 6139887. doi: 10.1093.
    >> Share

  361. HALLIDAY BP, Senior R, Pennell DJ
    Assessing left ventricular systolic function: from ejection fraction to strain analysis.
    Eur Heart J. 2021;42:789-797.
    >> Share

  362. CREA F
    New guidelines on adult congenital heart disease, the fantastic four in the treatment of heart failure, and also what happened in the last year in heart failure and valvular heart disease.
    Eur Heart J. 2021;42:551-554.
    >> Share


  363. Corrigendum to: The Year in Cardiovascular Medicine: Heart Failure and Cardiomyopathies. The Year in Cardiovascular Medicine 2020.
    Eur Heart J. 2021 Feb 11. pii: 6132731. doi: 10.1093.
    >> Share

  364. PETRIE MC, Lee MM, Lang NN
    EMPEROR-REDUCED reigns while EMPERIAL whimpers.
    Eur Heart J. 2021;42:711-714.
    >> Share

  365. WANG M, Zhou T, Song Y, Li X, et al
    Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank.
    Eur Heart J. 2021 Feb 2. pii: 6126215. doi: 10.1093/eurheartj/ehaa1031.
    >> Share

    January 2021
  366. LOCH A, Koh PS, Manokaran P
    Giant hepatic cyst masquerading as right heart failure.
    Eur Heart J. 2021 Jan 30. pii: 6124029. doi: 10.1093.
    >> Share

  367. FREY A, Homola GA, Henneges C, Muhlbauer L, et al
    Temporal changes in total and hippocampal brain volume and cognitive function in patients with chronic heart failure-the COGNITION.MATTERS-HF cohort study.
    Eur Heart J. 2021 Jan 26. pii: 6120261. doi: 10.1093.
    >> Share


  368. Corrigendum to: Does hypoperfusion outperform blood pressure as a better predictor in the risk stratification of acute heart failure?
    Eur Heart J. 2021;42:319.
    >> Share

  369. MASSIMO V, Carlo P
    Truly galactic?
    Eur Heart J. 2021;42:296-297.
    >> Share

  370. EVANS MA, Sano S, Walsh K
    Clonal haematopoiesis and cardiovascular disease: how low can you go?
    Eur Heart J. 2021;42:266-268.
    >> Share

  371. SMISETH OA, Aalen JM, Skulstad H
    Heart failure and systolic function: time to leave diagnostics based on ejection fraction?
    Eur Heart J. 2021 Jan 17. pii: 6075085. doi: 10.1093.
    >> Share

  372. BAUERSACHS J
    Heart failure drug treatment: the fantastic four.
    Eur Heart J. 2021 Jan 14. pii: 6099035. doi: 10.1093/eurheartj/ehaa1012.
    >> Share

  373. CSENGERI D, Sprunker NA, Di Castelnuovo A, Niiranen T, et al
    Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes.
    Eur Heart J. 2021 Jan 13. pii: 6090248. doi: 10.1093.
    >> Share

  374. HOLT A, Blanche P, Zareini B, Rajan D, et al
    Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study.
    Eur Heart J. 2021 Jan 11. pii: 6082772. doi: 10.1093/eurheartj/ehaa1058.
    >> Share

  375. PACKER M, Anker SD, Butler J, Filippatos G, et al
    Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
    Eur Heart J. 2021 Jan 11. pii: 6081935. doi: 10.1093.
    >> Share

  376. BUTLER J, Anker SD, Filippatos G, Khan MS, et al
    Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.
    Eur Heart J. 2021 Jan 9. pii: 6072066. doi: 10.1093/eurheartj/ehaa1007.
    >> Share

  377. CREA F
    Machine learning-guided phenotyping of dilated cardiomyopathy and treatment of heart failure by antisense oligonucleotides: the future has begun.
    Eur Heart J. 2021;42:139-142.
    >> Share

  378. DEVAUX Y, Badimon L
    CDR132L: another brick in the wall towards the use of miRNAs to treat cardiovascular disease.
    Eur Heart J. 2021;42:202-204.
    >> Share

  379. AGARWAL R, Kolkhof P, Bakris G, Bauersachs J, et al
    Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
    Eur Heart J. 2021;42:152-161.
    >> Share

  380. FURHOLZ M, Gisler F, Hunziker L, Huber AT, et al
    Posture dependent dynamic external outflow graft compression in HeartMate 3TM left ventricular assist device.
    Eur Heart J. 2021;42:205.
    >> Share

  381. BUENO H, Moura B, Lancellotti P, Bauersachs J, et al
    The year in cardiovascular medicine 2020: heart failure and cardiomyopathies.
    Eur Heart J. 2021 Jan 3. pii: 6060054. doi: 10.1093/eurheartj/ehaa1061.
    >> Share

    December 2020

  382. Corrigendum to: How to Diagnose Heart Failure with Preserved Ejection Fraction - The HFA-PEFF-SCORE An updated Consensus Statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Eur Heart J. 2020 Dec 29. pii: 6055039. doi: 10.1093/eurheartj/ehaa1016.
    >> Share

  383. ABRAHAM WT, Lindenfeld J, Ponikowski P, Agostoni P, et al
    Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
    Eur Heart J. 2020 Dec 22. pii: 6044442. doi: 10.1093.
    >> Share

  384. BAKER AH, Giacca M
    Antagonism of miRNA in heart failure: first evidence in human.
    Eur Heart J. 2020 Dec 18. pii: 6041762. doi: 10.1093.
    >> Share

  385. ROY R, Koch WJ
    Adding another GRK to the fire of heart failure.
    Eur Heart J. 2020 Dec 7. pii: 6025474. doi: 10.1093.
    >> Share

    November 2020
  386. PITT B, Byrd JB
    Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities.
    Eur Heart J. 2020 Nov 30. pii: 6012925. doi: 10.1093.
    >> Share

  387. ASSMUS B, Cremer S, Kirschbaum K, Culmann D, et al
    Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations.
    Eur Heart J. 2020 Nov 26. pii: 6006386. doi: 10.1093.
    >> Share

  388. SORIMACHI H, Obokata M, Takahashi N, Reddy YNV, et al
    Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction.
    Eur Heart J. 2020 Nov 23. pii: 5998959. doi: 10.1093.
    >> Share

  389. BOHM M, Mahfoud F
    J-curve revisited.
    Eur Heart J. 2020;41:4283.
    >> Share

  390. LIEW CH, McEvoy JW
    The diastolic blood pressure J-curve remains an observational research phenomenon that has not yet been proven as causal and should not be used to make invasive treatment decisions.
    Eur Heart J. 2020;41:4284-4285.
    >> Share

  391. FEDCHENKO M, Mandalenakis Z, Giang KW, Rosengren A, et al
    Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease-a nationwide study.
    Eur Heart J. 2020 Nov 21. pii: 5997447. doi: 10.1093.
    >> Share

  392. CLELAND JGF, Ferreira JP, Mariottoni B, Pellicori P, et al
    The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
    Eur Heart J. 2020 Nov 20. pii: 5993916. doi: 10.1093.
    >> Share

  393. ALFONSO F
    Heart Failure 2019.
    Eur Heart J. 2020 Nov 17. pii: 5986679. doi: 10.1093.
    >> Share

  394. TAUBEL J, Hauke W, Rump S, Viereck J, et al
    Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study.
    Eur Heart J. 2020 Nov 11. pii: 5974817. doi: 10.1093.
    >> Share

    October 2020

  395. Corrigendum to: Treatment of heart failure with reduced ejection fraction: the dawn of sodium-glucose cotransporter-2 inhibitors.
    Eur Heart J. 2020 Oct 22. pii: 5935857. doi: 10.1093.
    >> Share

  396. BATKAI S, Genschel C, Viereck J, Rump S, et al
    CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure.
    Eur Heart J. 2020 Oct 22. pii: 5934677. doi: 10.1093.
    >> Share

  397. CREA F
    The multiple causes and treatments of heart failure: focus on genetic and molecular mechanisms and non-pharmacological interventions.
    Eur Heart J. 2020;41:3769-3773.
    >> Share

  398. BONNET M, Champagnac A, Lantelme P, Harbaoui B, et al
    Endomyocardial biopsy findings in Kawasaki-like disease associated with SARS-CoV-2.
    Eur Heart J. 2020;41:3863-3864.
    >> Share

  399. PETTIT SJ
    HeartMate 3: real-world performance matches pivotal trial.
    Eur Heart J. 2020;41:3810-3812.
    >> Share

  400. LIUZZO G, Patrono C
    EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial.
    Eur Heart J. 2020 Oct 7. pii: 5918827. doi: 10.1093.
    >> Share

    September 2020
  401. CREA F
    Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors.
    Eur Heart J. 2020;41:3379-3383.
    >> Share

    July 2020
  402. HARARI R, Bangalore S
    Beta-blockers after acute myocardial infarction: an old drug in urgent need of new evidence!
    Eur Heart J. 2020 Jul 30. pii: 5879119. doi: 10.1093.
    >> Share

  403. LUSCHER TF
    How to slice the pie: heart failure subgroups and their clinical meaning.
    Eur Heart J. 2020;41:2339-2343.
    >> Share

  404. SCHMIDT IM, Verma A, Waikar SS
    Circulating plasma angiotensin-converting enzyme 2 concentrations in patients with kidney disease.
    Eur Heart J. 2020;41:3097-3098.
    >> Share

    May 2020
  405. LUSCHER TF
    Cardio-oncology and the future of heart failure.
    Eur Heart J. 2020;41:1709-1712.
    >> Share

  406. MILLER VM
    Universality of sex differences in cardiovascular outcomes: where do we go from here?
    Eur Heart J. 2020;41:1697-1699.
    >> Share

    April 2020
  407. LUSCHER TF
    Sex and gender and cardiovascular medicine: impact in diabetes, acute coronary syndromes, and heart failure.
    Eur Heart J. 2020;41:1311-1314.
    >> Share

    March 2020
  408. GOLDENBERG I, Huang DT, Nielsen JC
    The role of implantable cardioverter-defibrillators in asymptomatic patients with left ventricular dysfunction.
    Eur Heart J. 2020 Mar 25. pii: 5811613. doi: 10.1093.
    >> Share

  409. LUSCHER TF
    Ejection fraction to classify heart failure: are we using the right thing?
    Eur Heart J. 2020;41:1219-1222.
    >> Share

  410. MESSERLI FH, Bangalore S, Messerli AW, Raber L, et al
    The muddy waters of the J-curve and coronary revascularization.
    Eur Heart J. 2020 Mar 2. pii: 5771269. doi: 10.1093.
    >> Share

    December 2019
  411. MALMBORG M, Schmiegelow MDS, Norgaard CH, Munch A, et al
    Does type 2 diabetes confer higher relative rates of cardiovascular events in women compared with men?
    Eur Heart J. 2019 Dec 20. pii: 5682397. doi: 10.1093.
    >> Share

    November 2019
  412. GOLDENBERG I, Huang DT, Nielsen JC
    The role of implantable cardioverter-defibrillators and sudden cardiac death prevention: indications, device selection, and outcome.
    Eur Heart J. 2019 Nov 12. pii: 5622905. doi: 10.1093.
    >> Share

    September 2019
  413. WIJTVLIET EPJP, Tieleman RG, van Gelder IC, Pluymaekers NAHA, et al
    Nurse-led vs. usual-care for atrial fibrillation.
    Eur Heart J. 2019 Sep 23. pii: 5572602. doi: 10.1093.
    >> Share

    June 2019
  414. GENTILLE LORENTE DI
    Coconut atrium: a rare entity to cause pulmonary hypertension.
    Eur Heart J. 2019 Jun 4. pii: 5510776. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016